Brii Biosciences made its initial public offering (IPO) on the Hong Kong stock exchange on Tuesday. The 111.6 million shares—priced at $2.86 each—will raise nearly $320 million to advance the Sino-American biotech’s pipeline of more than 10 product candidates focused on infectious and central nervous system diseases, according to a company press release.

Brii’s portfolio includes candidate therapies for Covid-19, hepatitis B, HIV and multidrug-resistant Gram-negative bacterial…

Continuing its breakneck business pace, gene-editing specialist Graphite Bio—a Stanford spinout that just launched in September 2020—filed for an IPO last week.

San Francisco-based Graphite secured U.S. FDA clearance in December 2020 for Phase 1/2 trials of GPH101, its investigational sickle cell therapy.

Merck claimed a $9 billion payday as it finalized its spinoff of women’s health, biosimilars and legacy brands company Organon, which formally launched as an independent, publicly traded entity last week.

Merck will “likely” use the funds for a future acquisition, according to Endpoints News.


An Indian pharmacy chain backed by Serum Institute of India CEO Adar Poonawalla is planning an initial public offering, Hindustan Times reported Sunday, citing anonymous sources. The potential $160 million IPO would make Wellness Forever the first retail pharmacy chain listed on an Indian stock exchange, according to the article.

Poonawalla and his co-investors pumped more than $17 million into the company in November 2020, per local media.


Vaccine makers Vaccitech and Valneva separately filed plans last week for initial public offerings on Nasdaq.

Oxford-based Vaccitech is the Jenner Institute spinout that owns the technology underlying the AstraZeneca/Oxford Covid-19 vaccine. Its pipeline includes a Phase 1 MERS vaccine and a preclinical zoster shot.

France’s Valneva, already listed on Euronext and proposing to list American depositary shares via a new offering, is seeking regulatory clearance to advance its…